Table 1 Clinical and metabolic parameters of the diabetic patients with or without neuropathy and healthy control groups
From: Is calprotectin a novel biomarker of neuroinflammation in diabetic periferal neuropathy?
DNP(+) | DNP(−) | HC | P DNP(+)-DNP(−) | p DNP(+)-HC | P DNP(−)-HC | |
|---|---|---|---|---|---|---|
Age (years)* | 52.59 (±13.56) | 49.83 (±12.65) | 47.15 (±7.21) | 0.424 | 0.262 | 0.125 |
Gender (M/F) | 11/18 | 15/15 | 13/14 | 0.435 | 0.590 | 0.550 |
BMI (kg/m2) | 34.80 (±11.90) | 40.61 (±3.70) | 26.64 (±2.26) | <0.001 | 0.001 | 0.001 |
SBP (mmHg) | 130.00 (±20.00) | 135.00 (±10.00) | 120 (±15.00) | 0.042 | 0.054 | <0.001 |
DBP (mmHg) | 80 (±20.47) | 80 (±13.00) | 75.00 (±10.00) | 0.174 | 0.026 | <0.001 |
FPG (mg/dl) | 205 (±97.00) | 117 (±32.00) | 87 (±13.00) | <0.001 | 0.001 | 0.001 |
HbA1c (%) | 10.10 (±3.50) | 7.15 (±1.10) | 5.10 (±0.50) | <0.001 | 0.001 | 0.001 |
Total-C (mg/dl) | 180.50 (±71.00) | 222.00 (±38.00) | 109 (±28.00) | 0.001 | 0.528 | <0.001 |
HDL-C (mg/dl) | 38.50 (±17.00) | 48.50 (±8.00) | 50.00 (±9.00) | 0.003 | 0.002 | 0.183 |
LDL-C (mg/dl)* | 115.61 (±40.09) | 141.77 (±27.91) | 105.26 (±25.30) | 0.004 | 0.441 | <0.001 |
TG (mg/dl) | 214.00 (±95.00) | 173.50 (±67.00) | 136.00 (±39.00) | 0.041 | <0.001 | 0.001 |
Creatinine (mg/dl) | 0.85 (±0.29) | 0.86 (±0.16) | 0.89 (±0.11) | 0.167 | 0.102 | 0.163 |
Duration of DM (years) | 6 (±2.00) | 3 (±1.00) | 0.001 | |||
Calprotectin (ng/dl)* | 8.30 (±1.48) | 7.41 (±1.26) | 6.18 (±1.58) | 0.021 | <0.001 | 0.017 |
hsCRP (mg/dl) | 52.59 (±13.56) | 2.40 (±2.34) | 1.12 (±0.41) | <0.001 | <0.001 | 0.001 |
Medical Treatment | 11/18 | 0.141 | ||||
OAD (n, %) | 34.80 (±11.90) | 14 (46.7%) | ||||
Insulin (n, %) | 130.00 (±20.00) | 5 (16.7%) | ||||
OAD + Insulin (n, %) | 80 (±20.47) | 11 (36.7%) |